Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. INGN
INGN logo

INGN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Inogen Inc (INGN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.220
1 Day change
-2.20%
52 Week Range
9.130
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Inogen Inc (INGN) is not a strong buy for a beginner investor with a long-term strategy at this time. While the technical indicators show some positive momentum, the lack of significant trading trends, poor financial performance in the latest quarter, and no recent positive news or catalysts suggest that the stock does not currently present a compelling long-term investment opportunity. Additionally, there are no strong trading signals from Intellectia Proprietary Trading Signals to support immediate action.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 74.009, and moving averages are converging, showing no clear trend. The stock is trading near its resistance level (R1: 6.505), with a pre-market price of 6.62, slightly above R1 but below R2 (6.805).

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
4

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

  • Financial performance in 2025/Q4 shows a 100% drop in net income and EPS, along with a decline in gross margin (-4.85% YoY). No recent congress trading data or influential figure activity. Lack of significant trading trends and no strong AI or SwingMax trading signals.

Financial Performance

Revenue increased by 2.05% YoY to $81.72M in 2025/Q4. However, net income and EPS dropped by 100%, and gross margin declined to 43.12 (-4.85% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

Wall Street analysts forecast INGN stock price to rise
2 Analyst Rating
Wall Street analysts forecast INGN stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.360
sliders
Low
12
Averages
13
High
14
Current: 6.360
sliders
Low
12
Averages
13
High
14
B. Riley
NULL -> Buy
initiated
$14
AI Analysis
2025-06-17
Reason
B. Riley
Price Target
$14
AI Analysis
2025-06-17
initiated
NULL -> Buy
Reason
B. Riley initiated coverage of Inogen with a Buy rating and $14 price target.
B. Riley
Anderson Schock
Buy
initiated
$14
2025-06-17
Reason
B. Riley
Anderson Schock
Price Target
$14
2025-06-17
initiated
Buy
Reason
B. Riley analyst Anderson Schock last night initiated coverage of Inogen with a Buy rating and $14 price target. Inogen is a global leader in portable oxygen therapy, targeting chronic obstructive pulmonary disease patients, the analyst tells investors in a research note. The firm says the company's portable oxygen concentrators convert ambient air into medical-grade oxygen, allowing for greater patient mobility than traditional oxygen tanks. It believes Inogen represents a "compelling turnaround story" following a management transition in Q4 of 2023 focused on reducing friction among sales channels and on cost management strategies to drive sustainable and profitable growth. Riley views Inogen "deeply undervalued" and is encouraged by the company's turnaround momentum and five consecutive quarters of beating the Street's estimates.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for INGN
Unlock Now

People Also Watch